Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pipeline Review, H2 2015
Summary
Global Markets Directs, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pipeline Review, H2 2015, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview 7
Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Comparative Analysis 8
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics under Development by Companies 9
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Products under Development by Companies 14
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development 15
Baxalta Incorporated 15
GeNeuro SA 16
Mitsubishi Tanabe Pharma Corporation 17
Pfizer Inc. 18
Teijin Pharma Limited 19
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
fingolimod hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GL-2045 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
immune globulin (human) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
immune globulin (human) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibody for CIDP - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Recent Pipeline Updates 40
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects 46
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones 47
Featured News & Press Releases 47
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2015 7
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Comparative Analysis by Unknown Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Baxalta Incorporated, H2 2015 15
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2015 16
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 17
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc., H2 2015 18
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Limited, H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Assessment by Combination Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics - Recent Pipeline Updates, H2 2015 40
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2015 46
List of Figures
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2015 7
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Targets, H2 2015 22
Number of Products by Stage and Targets, H2 2015 22
Number of Products by Top 10 Routes of Administration, H2 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 25
Number of Products by Top 10 Molecule Types, H2 2015 27
Number of Products by Stage and Top 10 Molecule Types, H2 2015 27
